で公開中です！詳しく見る

Heartbeam

BEAT

時価総額 $2457万

0.4360 USD

+0.0045

1.04%

終値時点更新済み 10月16日 16:00 EDT

プレマーケット

時間外取引

0.4295

-0.0065

1.49%

1日

1.04%

5日間

-8.61%

1か月

6.5%

3か月

-24.2%

6か月

-46.17%

年初来

-82.06%

1年

-74.8%

5年間

-90.7%

10年間

-90.7%

概要： HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company's proprietary and patented technology platform captures the heart's electrical activity from three dimensions and synthesizes a 12-lead ECG from these signals. The company has received U.S. Food and Drug Administration (FDA) clearance for its ECG solutions.

従業員数： 16

ヘルスケア医療情報サービス

ニュース

ポジティブ

ニュートラル

ネガティブ

センチメント 3か月間

ポジティブ 14.3%

ニュートラル 85.7%

ネガティブ 0%

ニュートラル

HeartBeam Joins European EXIT-CVD Research Consortium to Advance At-Home ECG Monitoring for Early Detection of Acute Coronary Syndrome (ACS) in High-Risk Patients

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Joins European EXIT-CVD Research Consortium to Advance At-Home ECG Monitoring for Early Detection of Acute Coronary Syndrome.

HeartBeam Joins European EXIT-CVD Research Consortium to Advance At-Home ECG Monitoring for Early Detection of Acute Coronary Syndrome (ACS) in High-Risk Patients

ポジティブ

HeartBeam Secures FDA Designation for At-Home Heart Attack Detection System

Medical technology provider HeartBeam, Inc. (NASDAQ:BEAT) received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its at-home cardiac assessment tool.

HeartBeam Secures FDA Designation for At-Home Heart Attack Detection System

ニュートラル

HeartBeam Receives FDA Breakthrough Device Designation for Heart Attack Assessment

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Receives FDA Breakthrough Device Designation for Heart Attack Assessment.

HeartBeam Receives FDA Breakthrough Device Designation for Heart Attack Assessment

ニュートラル

HeartBeam, Inc. Letter to Shareholders

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc. Letter to Shareholders.

HeartBeam, Inc. Letter to Shareholders

ニュートラル

HeartBeam, Inc. (BEAT) Q2 2026 Earnings Call Transcript

HeartBeam, Inc. (BEAT) Q2 2026 Earnings Call Transcript

HeartBeam, Inc. (BEAT) Q2 2026 Earnings Call Transcript

ニュートラル

HeartBeam Reports Second Quarter 2026 Results

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Reports Second Quarter 2026 Results.

HeartBeam Reports Second Quarter 2026 Results

ニュートラル

HeartBeam to Host Second Quarter 2026 Results Conference Call on Thursday, August 13, 2026 at 4:30 p.m. Eastern Time

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam to Host Second Quarter 2026 Results Conference Call on Thursday, August 13, 2026 at 4:30 p.m. Eastern Time.

HeartBeam to Host Second Quarter 2026 Results Conference Call on Thursday, August 13, 2026 at 4:30 p.m. Eastern Time

ポジティブ

Zacks Investment Research

Healthcare IT is the Next AI Growth Story: 3 Stocks to Buy Now

Healthcare IT is emerging as AI's next growth story as providers adopt AI to cut costs & improve care. Here we present three stocks that are likely to benefit.

Healthcare IT is the Next AI Growth Story: 3 Stocks to Buy Now

ポジティブ

Zacks Investment Research

Bet On These 5 Top-Ranked Stocks With Increasing P/E Ratios

Tap these five stocks, W, DHR, ISRG, BEAT and CSW, with rising P/E ratios to try out an out-of-the-box approach.

Bet On These 5 Top-Ranked Stocks With Increasing P/E Ratios

ニュートラル

HeartBeam Completes Enrollment in Heart Attack Detection Pilot Study Ahead of Schedule

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam Completes Enrollment in Heart Attack Detection Pilot Study Ahead of Schedule.

HeartBeam Completes Enrollment in Heart Attack Detection Pilot Study Ahead of Schedule

ニュースランキングを見る

価格チャートは Lightweight Charts™ を使用して実装されています